Market capitalization | $3.59b |
Enterprise Value | $3.12b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 7.99 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-352.46m |
Free Cash Flow (TTM) Free Cash Flow | $-272.30m |
Cash position | $472.94m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
13 Analysts have issued a Immunovant Inc forecast:
13 Analysts have issued a Immunovant Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.29 -0.29 |
79%
79%
|
|
EBITDA | -352 -352 |
37%
37%
|
EBIT (Operating Income) EBIT | -352 -352 |
36%
36%
|
Net Profit | -323 -323 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
Head office | United States |
CEO | Peter Salzmann |
Employees | 207 |
Founded | 2018 |
Website | www.immunovant.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.